Redeye provides an in-depth take on AroCell’s Q1 report. Again, we emphasise that the company is trading at undemanding sales multiples, while enjoying solid sales growth with a controlled cost and cush burn, leaving a robust cash position – suitable for an eventual complementary acquisition of a product, in line with its proposed strategic overview.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/